Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $173000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 84.7% to $173000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $173000.0, a 84.7% decrease, with the full-year FY2025 number at $173000.0, down 84.7% from a year prior.
  • Other Non-Current Liabilities was $173000.0 for Q4 2025 at Beam Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $36.8 million in Q1 2021 to a low of $173000.0 in Q1 2023.
  • A 5-year average of $11.4 million and a median of $4.0 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 8836.41% in 2021, then plummeted 99.44% in 2023.
  • Beam Therapeutics' Other Non-Current Liabilities stood at $31.4 million in 2021, then crashed by 95.61% to $1.4 million in 2022, then skyrocketed by 97.61% to $2.7 million in 2023, then plummeted by 58.46% to $1.1 million in 2024, then crashed by 84.7% to $173000.0 in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Other Non-Current Liabilities are $173000.0 (Q4 2025), $6.7 million (Q3 2025), and $6.5 million (Q2 2025).